BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth

Multiple myeloma (MM) is a heterogeneous plasma cell malignancy and remains incurable. B-cell lymphoma-2 (BCL2) protein correlates with the survival and the drug resistance of myeloma cells. BH3 mimetics have been developed to disrupt the binding between BCL2 and its pro-apoptotic BCL2 family partne...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Deng, Jiusheng, Park, Dongkyoo, Wang, Mengchang, Nooka, Ajay, Deng, Qiaoya, Matulis, Shannon, Kaufman, Jonathan, Lonial, Sagar, Boise, Lawrence H., Galipeau, Jacques, Deng, Xingming
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5053685/
https://ncbi.nlm.nih.gov/pubmed/27049723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8513
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars